MedTrace Logo

Intratumoral Vusolimogene Oderparepvec (VO) in Combination With Pembrolizumab for Angiosarcoma

NCT06898970 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2026-05-08

No results posted yet for this study

Summary

This is a multicenter, open-label study of Intratumoral Vusolimogene Oderparepvec (VO) to investigate safety and estimate when used in combination with pembrolizumab for treating participants with angiosarcoma. This is the first study evaluating this novel combination in participants with advanced angiosarcoma who have progressed after prior immunotherapy.

Conditions

  • Angiosarcoma
  • Angiosarcoma, Adult

Interventions

BIOLOGICAL

Vusolimogene Oderparepvec (VO)

Given intratumorally

DRUG

Pembrolizumab

Given IV

Sponsors & Collaborators

  • Replimune, Inc.

    collaborator INDUSTRY

  • Varun Monga, MBBS

    lead OTHER

Principal Investigators

  • Varun Monga, MBBS · University of California, San Francisco

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-09
Primary Completion
2029-10-31
Completion
2029-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06898970 on ClinicalTrials.gov